Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system of autoimmune etiopathogenesis, and is characterized by various neurological symptoms. Glatiramer acetate and interferon-β are administered as first-line treatments for this disease. In non-responsive patients, several second-line therapies are available, including natalizumab; however, a percentage of MS patients does not respond, or respond partially. Therefore, it is of the utmost importance to develop a diagnostic test for the prediction of drug response in patients suffering from complex diseases, such as MS, where several therapeutic options are already available. By a machine learning approach, the UnCorrelated Shrunken Centroid algorithm was applied to identify a subset of genes of CD 4+ T cells that may predict the pharmacological response of relapsing-remitting MS patients to natalizumab, before the initiation of therapy. The results from the present study may provide a basis for the design of personalized therapeutic strategies for patients with MS.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3892/mmr.2019.10283|
|Codice identificativo ISI:||WOS:000474876100072|
|Codice identificativo Scopus:||2-s2.0-85068450610|
|Titolo:||Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment|
|Appare nelle tipologie:||1.1 Articolo in rivista|